24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Eye

Volumn 21, Issue 4, 2007, Pages 453-458

  Hepsen, I F ^a   Ozkaya, E ^b  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^b INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; EYE DROPS; LATANOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXFOLIATION SYNDROME; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OCULOPLETHYSMOGRAPHY; PARALLEL DESIGN; PRESSURE MEASUREMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 34147170051     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702243     Document Type: Article

References (22)

1. Bergea B, Bodin L, Svedberg B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106: 997-1005.
2. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142.
3. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 182-185.
4. Konstas AG, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 975-979.
5. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51-55.
6. O'Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 1991; 111: 491-500.
7. Konstas AG, Kozobolis VF, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 2004; 18: 1264-1269.
8. Konstas AG, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye 2003; 17: 41-46.
9. Konstas AG, Lake S, Maltezos AC, Holmes KT, Stewart WC. Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. Eye 2001; 15: 59-62.
10. Larsson LI. Intraocular pressure over 24 h after repeated administration of latanoprost 0.005% or timolol gelforming solution 0.5% in patients with ocular hypertension. Ophthalmology 2001; 108 1439-1444.
11. Larsson LI. Intraocular pressure over 24 h after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, crossover single center study. Acta Ophthalmol Scand 2001; 79: 567-571.
12. Mishima HK, Kiuchi Y, Takamatsu M, Racz P, Bito LZ. Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997; 41(Suppl 2): P139-P144.
13. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest ophthalmol Vis Sci 2000; 41: 2566-2573.
14. Konstas AG, Katsimbris JM, Lallos N, Boukaras GF, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112: 262-266.
15. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999; 40: 2912-2917.
16. Liu JH, Kripke DF, Hoffman RE, Twa MD, Loving RT, Rex KM et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci 1998; 39: 2707-2712.
17. Konstas AG. Therapeutic implication of IOP and OBF (scientific symposium). World Glaucoma Congress 6 July, 2005, Vienna, Austria.
18. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol 2005; 139: 320-324.
19. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005; 123: 898-902.
20. Parrish nd RK, Palmberg P, Sheu W-P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2003; 135: 688-703.
21. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. Bimatoprost Circadian IOP Study group. 24-h IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: A 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49(Suppl 1): P26-P35.
22. Hughes E, Spry P, Diamond J. 24-h monitoring of intraocular pressure in glaucoma management: A retrospective review. J Glaucoma 2003; 12: 232-236.